DALMANE
FLURAZEPAM HYDROCHLORIDE
Approval overview DALMANE is listed in Drugs@FDA under application 016721 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient FLURAZEPAM HYDROCHLORIDE Form and strength CAPSULE;ORAL - 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALEANT PHARM INTL Submission history Latest submission status date: 2009-03-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview DALMANE is listed in Drugs@FDA under application 016721 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient FLURAZEPAM HYDROCHLORIDE Form and strength CAPSULE;ORAL - 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor VALEANT PHARM INTL Submission history Latest submission status date: 2009-03-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.